FDA approves PROCYSBI(R) for Nephropathic Cystinosis

Parents who love their children can appreciate when treatments are available to bring hope and healing when their young ones are sick…

On August 17, 2015, one more ray of hope was added: FDA approval of PROCYSBI (R), a treatment for children aged 2-6 years old with Nephrotic Cystinosis. What opportunities does PROCYSBI(R) present? At least two:

PROCYSBI(R) gives children with Nephropathic Cystinosis a chance to start young…

Craig Langman, M.D., The Isaac A. Abt, M.D. Professor of Kidney Diseases, Feinberg School of Medicine says: “Strict adherence to cystine depleting therapy from as early an age as possible is critical to maintaining kidney function and leading longer, healthier lives for patients with cystinosis.”

PROCYSBI(R) gives children with Nephropathic Cystinosis a chance to bring stability…

It brings stability to both the child as well as to those providing care:

“The data in the two to six year old group confirm the maintenance of stable kidney function over time. Not only will this help these young patients with cystinosis, but the 12 hour dosing schedule for PROCYSBI could be a significant benefit to the caregivers of these young children,” says Dr. Langman, also Head of Kidney Diseases at Ann & Robert H. Lurie Children’s Hospital of Chicago and the lead investigator on the extension trial.

Want to find out more? Click below…

Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis (NASDAQ:RPTP)

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu